SCHEMBL4595886

SCHEMBL4595886

CC(C)(C)OC(=O)NC(Cc1ccc(-c2ccc(C=O)cc2)cc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 7/20 0.58
CTSK P43235 6/20 0.58
ACE P12821 3/20 0.57
ITGB3 P05106 2/20 0.56
ITGA2B P08514 2/20 0.56
ITGA4 P13612 2/20 0.54
ITGB7 P26010 2/20 0.54
PTPN1 P18031 2/20 0.52
MME P08473 2/20 0.52
ACE2 Q9BYF1 2/20 0.52
PPARA Q07869 3/20 0.52
PPARG P37231 2/20 0.52
CTSB P07858 2/20 0.50
CTSL P07711 1/20 0.50
BCL2 P10415 1/20 0.49
CPA1 P15085 1/20 0.48
ITGB1 P05556 1/20 0.48
ITGAV P06756 1/20 0.48
ITGB5 P18084 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14021749 1.00 CTSS (0.58) CTSSCTSKACEITGB3ITGA2B
SCHEMBL5227204 0.96 ACE (0.60) CTSSCTSKACEITGB3ITGA2B
SCHEMBL23704405 0.96 ACE (0.60) CTSSCTSKACEITGB3ITGA2B
SCHEMBL3867713 0.91 ITGB3 (0.60) CTSSCTSKACEITGB3ITGA2B
SCHEMBL3867720 0.91 ITGB3 (0.60) CTSSCTSKACEITGB3ITGA2B
SCHEMBL2853703 0.90 ACE (0.57) CTSSCTSKACEITGB3ITGA2B
SCHEMBL2856227 0.90 ACE (0.57) CTSSCTSKACEITGB3ITGA2B
SCHEMBL2853701 0.90 ACE (0.57) CTSSCTSKACEITGB3ITGA2B
SCHEMBL1326276 0.89 CTSS (0.72) CTSSCTSKACEITGB3ITGA2B
SCHEMBL1325182 0.89 CTSS (0.72) CTSSCTSKACEITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261981-A1 NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS BEXEL PHARMACEUTICALS, INC. 2008-10-23 US disclosed
US-20080175795-A1 Novel derivatives of amino acids for treatment of obesity and related disorders BEXEL PHARMACEUTICALS, INC. 2008-07-24 US disclosed
US-7399786-B2 Derivatives of amino acids for treatment of obesity and related disorders BEXEL PHARMACEUTICALS, INC. (US) 2008-07-15 US disclosed
EP-1907352-A2 NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS Bexel Pharmaceuticals Inc (US) 2008-04-09 EP disclosed
WO-2007005774-A9 NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS BEXEL PHARMACEUTICALS INC (US) 2007-03-08 WO disclosed
WO-2007005774-A2 NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS BEXEL PHARMACEUTICALS, INC. (US) 2007-01-11 WO disclosed
US-20070004725-A1 Novel derivatives of amino acids for treatment of obesity and related disorders BEXEL PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080175795-A1 Novel derivatives of amino acids for treatment of obesity and related disorders GPR119, AADAT, FABP4 CTSS 3190/4885CTSK 2275/4885ACE 907/4885
US-20070004725-A1 Novel derivatives of amino acids for treatment of obesity and related disorders GPR119, AADAT, FABP4 CTSS 3190/4885CTSK 2275/4885ACE 907/4885
US-20080261981-A1 NOVEL DERIVATIVES OF AMINO ACIDS FOR TREATMENT OF OBESITY AND RELATED DISORDERS GPR119, AADAT, FABP4 CTSS 3190/4885CTSK 2275/4885ACE 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.